NEVRO CORP's ticker is and the CUSIP is 64157FAC7. A total of 24 filers reported holding NEVRO CORP in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $933 | +1.0% | 0 | – | 0.00% | 0.0% |
| Q2 2023 | $924 | -1.7% | 0 | – | 0.00% | 0.0% |
| Q1 2023 | $940 | +2.5% | 0 | – | 0.00% | 0.0% |
| Q4 2022 | $917 | -99.9% | 0 | – | 0.00% | 0.0% |
| Q3 2022 | $946,000 | +1.6% | 0 | – | 0.00% | 0.0% |
| Q2 2022 | $931,000 | -92.8% | 0 | -100.0% | 0.00% | -93.3% |
| Q1 2022 | $12,972,000 | -2.9% | 12,000,000 | 0.0% | 0.02% | +7.1% |
| Q4 2021 | $13,355,000 | -50.6% | 12,000,000 | -40.0% | 0.01% | -53.3% |
| Q3 2021 | $27,012,000 | +29.9% | 20,000,000 | +66.7% | 0.03% | +30.4% |
| Q2 2021 | $20,790,000 | -3.7% | 12,000,000 | -14.3% | 0.02% | -11.5% |
| Q1 2021 | $21,586,000 | -2.5% | 14,000,000 | +15.3% | 0.03% | -7.1% |
| Q4 2020 | $22,143,000 | +48.1% | 12,146,000 | +25.9% | 0.03% | +33.3% |
| Q3 2020 | $14,954,000 | +43.1% | 9,646,000 | +26.2% | 0.02% | +31.2% |
| Q2 2020 | $10,447,000 | – | 7,646,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BRAIDWELL LP | 109,251,000 | $102,018,584 | 3.22% |
| Opti Capital Management, LP | 19,500,000 | $18,574 | 1.34% |
| Context Capital Management, LLC | 10,702 | $10,207 | 0.82% |
| PFM Health Sciences, LP | 17,500,000 | $16,341,500 | 0.77% |
| LINDEN ADVISORS LP | 21,366,000 | $19,993,448 | 0.20% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 1,595,000 | $1,543,041 | 0.03% |
| CAPSTONE INVESTMENT ADVISORS, LLC | 6,667,000 | $6,225,645 | 0.03% |
| Rock Springs Capital Management LP | 500,000 | $472,128 | 0.01% |
| LAZARD ASSET MANAGEMENT LLC | 0 | $933 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |